COLY-MYCIN S (colistin sulfate) by Pfizer is clinical pharmacology colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Approved for superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
COLY-MYCIN S is a fixed-dose combination antibiotic suspension containing colistin sulfate, neomycin sulfate, thonzonium bromide, and hydrocortisone acetate. It treats superficial bacterial infections of the external auditory canal caused by susceptible gram-positive and gram-negative organisms. The formulation works through multiple mechanisms: colistin and neomycin disrupt bacterial cell membranes and protein synthesis, hydrocortisone reduces inflammation, and thonzonium bromide enhances tissue penetration.
As a pre-launch product, COLY-MYCIN S offers limited immediate commercial activity; career opportunities will depend on approval success and launch execution under Pfizer's leadership.
CLINICAL PHARMACOLOGY Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a…
Worked on COLY-MYCIN S at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
COLY-MYCIN S offers entry or mid-level commercial career opportunities within Pfizer's primary care or otolaryngology franchise, contingent on regulatory approval and successful market launch. Career growth potential is moderate given the mature indication and competitive intensity; differentiation will depend on launch execution and payer acceptance.